
















Kubicek,  S.,  O’Sullivan,  R.J.,  August,  E.M., 
Hickey,  E.R.,  Zhang, Q.,  Teodoro, M.L.,  Rea, 
S., Mechtler, K., Kowalski, J.A., Homon, C.A., 
et al. (2007). Mol. Cell 25, 473–481.
Kuzmichev,  A.,  Margueron,  R.,  Vaquero,  A., 







Sparmann,  A.,  and  van  Lohuizen, M.  (2006). 
Nat. Rev. Cancer 6, 846–856.
Squazzo,  S.L., O’Geen, H.,  Komashko,  V.M., 








A.,  Bernard,  D.,  Vanderwinden,  J.M.,  et  al. 
(2006). Nature 439, 871–874.
Villa,  R.,  Pasini,  D.,  Gutierrez,  A.,  Morey,  L., 
Occhionorelli,  M.,  Viré,  E.,  Nomdedeu,  J.F., 
Jenuwein,  T., Pelicci, P.G., Minucci, S.,  et  al. 
(2007). Cancer Cell, this issue.The Potential of new Tumor  
endothelium-specific Markers  
for the Development of Antivascular Therapy





Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anti-
cancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium 
have been identified during the last decade. However, due to the expression in both physiological 
and tumor angiogenesis, only a few targets have been developed for clinical therapeutics. By 
thorough SAGE analysis of mouse endothelial cells isolated from various normal resting tissues, 
regenerating liver, and liver-metastasized tumor, Seaman and colleagues in this issue of Cancer 
Cell have demonstrated organ-specific endothelial markers, physiological angiogenesis endothelial 
markers, and tumor endothelial markers and revealed striking differences between physiological 
and pathological angiogenesis.Angiogenesis  is  a  hallmark  of  solid 
tumors.  Disruption  of  tumor  angio-
genesis  by  blocking  proangiogenic 
growth  factors  or  shutdown  of  the 
established  tumor  blood  vessels 
by  vascular  targeting  agents  has 
demonstrated  therapeutic  effects  in 
human cancer. The vascular-disrupt-
ing  effect  can  be  mediated  directly 
by  toxic  agents  or  selectively  deliv-
ered by antibody or peptide targeting 
(Neri and Bicknell, 2005). The recent 
successful  blockade  of  the  VEGF 478  Cancer Cell 11, June 2007 ©2007 Epathway  in  several  major  cancers 
prolonged survival in phase III clinical 
trials  and  has  encouraged  the  iden-
tification  of  new  tumor  endothelial 
markers (TEMs).
Early  attempts  to  identify  tumor 
vascular targets focused on the study 
of  in  vitro  endothelial  cell  (EC)-iso-




of molecular markers  predominantly lsevier Inc.expressed  on  angiogenic  vessels, 
but  in  both  tumor  and  physiological 
angiogenesis. With the advent of new 
techniques, a great number of tumor 
endothelial  molecules  have  been 
identified  during  the  last  decade.  In 




used  to  deliver  peptides  that  selec-
tively  recognize  organ-specific  and 






In  an  earlier  study  from  St.  Croix 





colorectal  tumor  and  those  isolated 
from  its  adjacent  normal  tissue, 
including  46  specifically  elevated 












approach  further  for  several  tumor 
types,  usually  comparing  tumor 
endothelium  with  adjacent  normal 
tissue endothelium. SAGE analysis of 
human brain ECs revealed 14 glioma 
endothelial  markers  upregulated  in 
ECs  isolated  from  three  grade-III/IV 
gliomas  compared  to  ECs  from  two 
nonneoplastic temporal lobe tissues. 
Of these, 12 are known to be present 
on  the  cell  surface  or  secreted.  In 
situ  hybridization  demonstrated  the 
overexpression of the G protein-cou-
pled  receptor  RDC1  in  both  brain 
and  colon  tumor  ECs  (Madden  et 
al.,  2004). SAGE-analysis of purified 
ECs  from  freshly  resected  speci-
mens of two invasive breast cancers 
and  one  normal  reduction  mammo-
plasty  revealed  29  genes  that  were 
expressed  at  least  6-fold  higher  in 
breast  tumor  ECs  than  in  normal 
breast ECs; five of these were 5-fold 
higher  in  breast  tumor  than  in  both 
colon  and  brain  tumors.  HEYL,  one 
of  the TEMs, was  restricted  to  inva-





pression  subtractive  hybridization  to 
compare gene-expression profiles of 
the ECs isolated from five human colon figure 1. schematic Diagram Depicting the Identification of Organ-specific, Physi-
ological, and Tumor Angiogenesis Markers
Various mouse ECs were isolated from eight normal resting tissues (including brain, heart, kid-
ney, liver, lung, muscle, spleen, and intestine), regenerating liver (24, 48, and 72 hr posthepate-
ctomy),  two  types of  liver-metastasized, and  three  types of subcutaneously-implanted  tumors 






pared  to  nonangiogenic  ECs  of  all  resting  tissues,  and  13  tumor  endothelial markers  (TEMs) 
overexpressed  at  least  10-fold  or  higher  in  tumor  ECs  compared  to  normal  resting  ECs  and 
regenerating liver ECs (A). Of the 13 TEMs identified (B), seven of them including CD276 (B7-H3), 








tal  tumor-conditioned  HUVEC  and 
quiescent  HUVEC  cells.  Forty-six 





ECs  compared  with  angiogenic 
(placental) and nonangiogenic ECs. 
Four  of  these  markers  (vimentin, 
CD59,  IGFBP7,  and  HMGB1)  were 
overexpressed  on  tumor  vascula-
ture at  the protein  level. Antibodies 
targeting  these  markers  inhibited 
angiogenesis in vitro and in vivo and targeting  endothelial  vimentin  in  a 
xenograft  mouse  model  markedly 
inhibited  tumor  growth  and  tumor 
angiogenesis.
Following the isolation of ECs from 






expressed  genes  in  ovarian  tumor 
ECs.  Among  them,  all  six  validated 
genes were  overexpressed  in  tumor 





PreviewsBuckanovich  et  al.  (2007)  used 






tumor  vascular  markers  that  were 
highly  expressed  in  purified  tumor 




normal  tissues,  including  placen-
tal  and  female  reproductive  tissues 
with  physiological  angiogenesis. 
The  expression  of  STC2,  EGFL6, 
and FZD10  in ovarian vascular cells 
was  significantly  associated  with 
decreased disease-free interval.





obvious  surgical  reasons.  An  ideal 
TEM  would  discriminate  between 
tumor angiogenesis and physiologi-
cal  or  regenerative  angiogenesis, 
such  as  those  occurring  in  female 
reproductive and wound healing tis-




genesis  of  corpus  luteum  formation 
and wound healing, or even in normal 
ECs  from  various  organs,  though  at 
a  low  level  (Bonuccelli  et  al.,  2005; 
Buckanovich et al., 2007; St. Croix et 




ficiently  pure  EC  populations  from 
natural  tumors, organ-matched nor-
mal  and  regenerative  tissues,  and 
other resting tissues.









analyzed gene-expression profiles in 480  Cancer Cell 11, June 2007 ©2007 Emouse ECs  that were  isolated  from 
various normal tissues, regenerating 
liver,  and  liver-metastasized  tumors 
as well as subcutaneously implanted 
tumors. Twenty-seven brain endothe-
lial markers  and 15  liver  endothelial 
markers were  identified to be highly 
expressed  in  resting  brain  or  liver 
ECs  compared  to  normal  ECs  from 
other  tissues.  In  addition,  12  AEMs 
were overexpressed with 15- to 100-
fold higher  in regenerating liver ECs 
compared  to  nonangiogenic  ECs, 
and  most  of  AEMs  have  expected 
roles  in  cell-cycle  control.  AEMs 
were also upregulated in tumor ECs, 
highlighting  the  overlapping  proc-
esses  in  physiological  and  tumor 
angiogenesis.
However, 13 TEMs were expressed 
at  least  10-fold  higher  in  tumor  ECs 
than  in normal ECs and  regenerating 
liver ECs, of which seven TEMs were 




ious  tumor  types.  Further  investiga-
tion of CD276,  the most differentially 
expressed TEM, with multiple human 













remain  to  be  further  investigated. 
The  gene-expression  profiling  of 
the  ECs  from  xenograft  or  allograft 
tumors could be very different  from 
those  in  endogenously  formed  pri-
mary and metastatic tumors. Moreo-
ver, transcriptional profiling at a later 






The  threshold  for  analysis  of  these 
genes was set at 10-fold, but analy-lsevier Inc.sis  of  genes  with  lower  differential 
may  be  just  as  important.  Splice 
variants, which have been shown to 





of  metastasis,  interindividual  vari-




and  liver  is  also  important.  In  vivo 
imaging studies should help resolve 
some of these issues.
The  most  important  point  per-
haps  is  still  the specificity of  these 
TEMs. Four of them (CD276, CD137, 
PTPRN, and CD109) had been shown 
to  be  involved  in  regulating  inflam-




evaluation  of  these  TEMs  for  their 
tissue/cell specificity and biological 




mechanistic?  What  is  their  role  in 
angiogenesis  and  cell  trafficking, 
e.g., attracting endothelial progeni-
tors  and  immune  cells?  What  are 
the  mechanisms  for  their  upregu-
lation? Could  they  be  regulated  by 
cytokines secreted by tumor, which 
activate  distant  sites  of metastasis 
to  prepare  the  “soil”?  If  so,  early 
therapy  could  be  used  to  prevent 
establishing  growth  of  microme-
tastasis. The findings of Seaman et 
al.  (2007)  provide  a  great  resource 
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